Results 201 to 210 of about 4,786,755 (237)
Some of the next articles are maybe not open access.
2016
Light-chain (AL) amyloidosis is the most common cause of acquired systemic amyloidosis. It is a highly heterogeneous disease with a wide spectrum of clinical presentation. Prognosis of AL amyloidosis depends on organ, particularly cardiac, involvement.
Amara S. Hussain, Anita D’Souza
openaire +1 more source
Light-chain (AL) amyloidosis is the most common cause of acquired systemic amyloidosis. It is a highly heterogeneous disease with a wide spectrum of clinical presentation. Prognosis of AL amyloidosis depends on organ, particularly cardiac, involvement.
Amara S. Hussain, Anita D’Souza
openaire +1 more source
Treatment of immunoglobulin light chain amyloidosis
Current Hematologic Malignancy Reports, 2009No therapy is uniformly effective in the management of immunoglobulin light chain amyloidosis (AL amyloidosis). Despite the common generalization, therapy is highly effective. Options available to patients with AL amyloidosis include high-dose therapy, but this is applicable to only about one fourth of patients.
Morie A, Gertz, Steven R, Zeldenrust
openaire +2 more sources
Immunoglobulin Light Chain Systemic Amyloidosis
2016Immunoglobulin light chain amyloidosis (AL) is a rare, complex disease caused by misfolded free light chains produced by a usually small, indolent plasma cell clone. Effective treatments exist that can alter the natural history, provided that they are started before irreversible organ damage has occurred.
Angela, Dispenzieri, Giampaolo, Merlini
openaire +2 more sources
Free Light Chains of Immunoglobulins in Amyloidosis
Acta Medica Scandinavica, 1979ABSTRACT Monomeric (M) and dimeric (D) forms of free light chains in serum have been measured by a sensitive radioimmunoassay in eight patients with amyloidosis without monoclonal proteins. Significantly elevated concentrations of D lambda chains were demonstrated in two of four patients with localized amyloidosis.
J, Sølling, K, Sølling
openaire +2 more sources
Amyloid Formation in Light Chain Amyloidosis
Current Topics in Medicinal Chemistry, 2013Light chain amyloidosis is one of the unique examples within amyloid diseases where the amyloidogenic precursor is a protein that escapes the quality control machinery and is secreted from the cells to be circulated in the bloodstream. The immunoglobulin light chains are produced by an abnormally proliferative monoclonal population of plasma cells that
openaire +2 more sources
Systemic Immunoglobulin Light-Chain Amyloidosis
Clinical Lymphoma and Myeloma, 2006Amyloidosis is a rare disease in which amyloid fibrils compromise organ function and lead to death. Systemic immunoglobulin light-chain amyloidosis, usually caused by free light chains (FLCs) made by clonal plasma cells, is the most frequent type. Hereditary and senile systemic amyloidosis are less frequent types.
openaire +2 more sources
Immunoglobulin Light Chain and Systemic Light-Chain Amyloidosis
2007Light-chain amyloidosis (AL) is characterized by the clonal expansion of plasma B cells that secrete large amounts of monoclonal immunoglobulin light chains. The free light chains circulate in serum and form amyloid fibrils on vital organs such as the kidney, heart, and liver causing organ failure and eventually death.
Marina Ramirez-Alvarado +5 more
openaire +1 more source
Managing Systemic Light-Chain Amyloidosis
Journal of the National Comprehensive Cancer Network, 2007Amyloidosis is a rare disease in which a specific protein is deposited as aggregated interstitial fibrils that can compromise organ function and lead to death. Immunoglobulin (Ig) light-chain amyloidosis (AL), caused by the monoclonal gammopathy of a plasma cell dyscrasia, is the most common type.
openaire +2 more sources
[Amyloid light chain amyloidosis].
Brain and nerve = Shinkei kenkyu no shinpo, 2014Primary amyloid light chain (AL) amyloidosis is the most common and most aggressive form of systemic amyloidosis. In AL amyloidosis, the products of free light chains (FLCs) of monoclonal amyloidogenic plasma cells deposit in the heart, kidneys, liver, gastrointestinal tract, autonomic nerve systems, and soft tissues, consequently leading to ...
Kenshi, Suzuki, Toshiko, Shimizu
openaire +1 more source
Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis
Cells, 2021Giovanni Palladini +2 more
exaly